PHXM PHAXIAM THERAPEUTICS

Results of the Combined General Meeting of 28 June 2024

Results of the Combined General Meeting of 28 June 2024

Lyon (France) and Cambridge (MA, US), 28 June 2024 - 5.45 pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, announces the results of the shareholder vote following the Combined General Meeting held today, 28 June 2024, at the head office, located 60 avenue Rockefeller, 69008, Lyon.

The shareholders approved all the resolutions on which the Board of Directors recommended a favorable vote. The resolutions adopted were as follows:

  • Approval of the annual financial statements and consolidated financial statements for the year ended 31 December 2023,
  • Allocation of the result of the year,
  • Approval of the Statutory Auditors' special report on regulated agreements and commitments,
  • Approval of the total remuneration and benefits paid or granted in respect of the financial year ended 31 December 2023 to Gil Beyen, Jean-Paul Kress, Thibaut du Fayet and Didier Hoch and of the remuneration policy for executive officers and members of the Board of Directors,
  • Approval of the terms and conditions of the stock option plan adopted by the Board of Directors on 14 November 2023,
  • Confirmation of the appointment of Valérie Faillat as Director,
  • Delegation of powers to the Board of Directors to issue shares or other securities convertible into shares to be issued immediately or in the future by the Company, with or without pre-emptive subscription rights for shareholders,
  • Authorization for the Board of Directors to grant free shares, share subscription and/or share purchase options and/or to issue share warrants to officers and employees of the Company or companies in the PHAXIAM Therapeutics group,
  • Amendments to the by-laws.



The documentation and full results of all the resolutions adopted can be consulted on the Company's website () in the section .

About PHAXIAM Therapeutics

PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.

PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

For more information, please visit

Contacts

PHAXIAM

Eric Soyer

COO & CFO

38





NewCap

Mathilde Bohin / Dušan Orešanský

Investor Relations

Arthur Rouillé

Media Relations

94



Forward-looking information

This press release contains forward-looking statements, forecasts and estimates with respect to the clinical programs, development plans, business and regulatory strategy and anticipated future performance of PHAXIAM and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. All statements contained in this press release other than statements of historical facts are forward-looking statements. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond PHAXIAM's control. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Investor should carefully read the risk factors section of the Company which can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), including in the Company’s 2023 Universal Registration Document (Document d’Enregistrement Universel) filed with the AMF on April 5, 2024 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. PHAXIAM disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in PHAXIAM’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.

Attachment



EN
28/06/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PHAXIAM THERAPEUTICS

 PRESS RELEASE

PHAXIAM THERAPEUTICS annonce le lancement d’un processus de recherche ...

LYON, France--(BUSINESS WIRE)-- Regulatory News: PHAXIAM Therapeutics (Euronext : PHXM - FR001400K4B1), ci-après « la Société » ou « PHAXIAM », société biopharmaceutique spécialisée dans le développement de traitements innovants pour les infections bactériennes résistantes, annonce le lancement d’un appel d’offres ouvert jusqu’au 11 avril 2025. L’administrateur judiciaire a publié une annonce dans le journal Les Échos (parution le vendredi 14 mars 2025) en vue de rechercher des repreneurs potentiels dans le cadre d’un plan de cession. Les personnes intéressées souhaitant répondre à l’appel ...

 PRESS RELEASE

PHAXIAM annonce l’ouverture d’une procédure de redressement judiciaire...

LYON, France--(BUSINESS WIRE)-- Regulatory News: PHAXIAM Therapeutics (Euronext : PHXM - FR001400K4B1), ci-après « la Société » ou « PHAXIAM », société biopharmaceutique spécialisée dans le développement de traitements innovants pour les infections bactériennes résistantes, annonce que, à la suite de la demande de la Société, le Tribunal de Commerce de Lyon a décidé le 6 mars 2025 l’ouverture d’une procédure de redressement judiciaire. Dans un contexte de financement extrêmement difficile pour les biotechs et les small caps cotées et après plusieurs initiatives infructueuses de refinancement...

 PRESS RELEASE

PHAXIAM THERAPEUTICS : COMMUNIQUE DE PRESSE RELATIF A LA SUSPENSION DE...

LYON, France--(BUSINESS WIRE)-- Regulatory News: PHAXIAM Therapeutics (Euronext : PHXM - FR001400K4B1), a demandé à Euronext de suspendre la cotation de son titre admis sur le marché Euronext d'Euronext Paris à compter de la publication du présent communiqué, dans l'attente de la publication d'un prochain communiqué de presse. À propos de PHAXIAM Therapeutics PHAXIAM est une société biopharmaceutique qui développe des traitements innovants contre les infections bactériennes résistantes, responsables de nombreuses infections graves. La société s'appuie sur une approche innovante basée sur l'...

 PRESS RELEASE

PHAXIAM Therapeutics annonce son calendrier financier 2025

LYON, France--(BUSINESS WIRE)-- Regulatory News: PHAXIAM Therapeutics (Euronext : PHXM – FR0011471135), société biopharmaceutique qui développe des traitements innovants pour les infections bactériennes sévères et résistantes, annonce aujourd’hui son calendrier financier pour 2025. Calendrier des publications financières 20251 Point sur l’activité et résultats financiers annuels 2024 : communiqué de presse le jeudi 13 mars 2025 après la clôture du marché, suivi d'un webinaire en français à 18h00 Assemblée générale des actionnaires le mardi 24 juin 2025 Point sur l’activité et résu...

 PRESS RELEASE

PHAXIAM Therapeutics annonce des données cliniques actualisées issues ...

LYON, France--(BUSINESS WIRE)-- Regulatory News: PHAXIAM Therapeutics (Euronext : PHXM - FR0011471135), société biopharmaceutique qui développe des traitements innovants pour les infections bactériennes sévères et résistantes, fait aujourd'hui le point sur les données cliniques issues de patients traités sous statut compassionnel avec ses phages. Depuis 2017, PHAXIAM a traité plus de 120 patients sous statut compassionnel, la majorité souffrant d'infections ostéoarticulaires sur prothèses (PJI) de la hanche ou du genou. Si la grande majorité d’entre eux a été traitée en France, de plus en ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch